RNA
ATRIUM THERAP (RNA)
NASDAQ
$12.90-$0.04 (-0.31%)
Price as of Jun 23, 2026 11:45 AM EDT
  • $221.3M
    Market Cap
  • -55.61%
    1-Year Change
  • Biotechnology
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 46
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

No data found

No data found

Peers

Statistics

More
Day Range
$12.59
$12.96
$12.94
1-Year Range
$11.55
$72.93
$12.94
Latest Close$12.94
Change
+$0.28 (+2.16%)
Volume221,017
Market Cap$221.3M
Shares Outstanding17.1M
P/E (TTM)-13.31
Diluted EPS (TTM)-$0.97
Enterprise Value-$46.5M

Information as of 06/22/2026

Company Profile

ATRIUM THERAPEUTICS INC
ATRIUM THERAPEUTICS INC
https://atriumtherapeutics.com
$221.3M
Market Cap
-$16.6M
Net Income
Sector: Healthcare
Industry: Biotechnology
10578 Science Center Drive, San Diego, CA, United States, 92121
619 876 0700

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.

Key Executives

  • Stephanie Kenney
  • Rocio Martin Hoyos
  • Kathleen Gallagher
  • Steven George Hughes
  • Brendan Winslow

Current Ownership Distribution

  • Institutions1.7B (79.87%)
  • Mutual Funds405.0M (19.59%)
  • Insiders11.2M (0.54%)
  • Other0 (0.00%)